Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.07 to $114.14 on Friday after Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS).